Improving responses to dual PI3K/BCL2 inhibition in lymphomas: results of a pharmacological screen with over 1, 400 compounds. (October 2022) - Arribas, A.; Chiappa, M.; Napoli, S.; Cannas, E.; Cascione, L.; Spriano, F.; Tarantelli, C.; Rossi, D.; Zucca, E.; Alimonti, A.; Stathis, A.; Damia, G.; et al.